Get the Stockscreener App
8.85
1.34%
-0.12
Regenxbio Inc stock is traded at $8.85, with a volume of 830.37K.
It is down -1.34% in the last 24 hours and down -5.95% over the past month.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
See More
Previous Close:
$8.97
Open:
$8.79
24h Volume:
830.37K
Relative Volume:
0.77
Market Cap:
$443.92M
Revenue:
$89.04M
Net Income/Loss:
$-241.08M
P/E Ratio:
-1.6825
EPS:
-5.26
Net Cash Flow:
$-194.72M
1W Performance:
-8.86%
1M Performance:
-5.95%
6M Performance:
-10.79%
1Y Performance:
-38.33%
1-Day Range:
$8.22
$8.915
1-Week Range:
$8.22
$9.83
52-Week Range:
$5.035
$15.36
Regenxbio Inc Stock (RGNX) Company Profile
Name
Regenxbio Inc
Sector
Industry
Phone
240-552-8181
Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
8.85 | 487.06M | 89.04M | -241.08M | -194.72M | -5.26 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Downgrade | Goldman | Buy → Neutral |
| Feb-07-25 | Resumed | Raymond James | Outperform |
| Nov-15-24 | Resumed | Morgan Stanley | Overweight |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jun-07-24 | Initiated | Goldman | Buy |
| Mar-11-24 | Initiated | H.C. Wainwright | Buy |
| Mar-08-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-21-24 | Resumed | Raymond James | Outperform |
| Nov-01-23 | Initiated | Stifel | Buy |
| Jun-02-23 | Initiated | Robert W. Baird | Outperform |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Wedbush | Neutral |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jan-06-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-20-19 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Jun-18-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-14-19 | Resumed | Raymond James | Outperform |
| Jun-05-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-25-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-05-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-17-18 | Reiterated | Chardan Capital Markets | Buy |
| Nov-08-18 | Reiterated | BofA/Merrill | Neutral |
| Aug-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-23-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-10-18 | Reiterated | Chardan Capital Markets | Buy |
| May-09-18 | Reiterated | Barclays | Overweight |
| Apr-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-13-18 | Initiated | Mizuho | Neutral |
| Nov-09-17 | Resumed | Morgan Stanley | Overweight |
View All
Regenxbio Inc Stock (RGNX) Latest News
REGENXBIO announces royalty monetization agreement for up to $250M - MSN
REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth - Investing.com Australia
REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth By Investing.com - Investing.com South Africa
REGENXBIO’s $250 Million Royalty Bond Agreement with HealthCare Royalty - Global Legal Chronicle
Coave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS Diseases - GlobeNewswire Inc.
Regenxbio at RBC Conference: Strategic Moves and Clinical Progress - Investing.com Australia
Regenxbio at RBC Conference: Strategic Moves and Clinical Progress By Investing.com - Investing.com Nigeria
REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million | RGNX Stock News - GuruFocus
Stifel maintains Buy on Regenxbio, price target at $40 By Investing.com - Investing.com Nigeria
Stifel maintains Buy on Regenxbio, price target at $40 - Investing.com
Regenxbio Secures $250 Million In New Royalty Bonds - Finimize
REGENXBIO secures $150 million to extend cash runway By Investing.com - Investing.com South Africa
Regenxbio (RGNX) Secures $250M Royalty Bond Deal for Non-Dilutiv - GuruFocus
REGENXBIO (RGNX) Secures $250 Million Non-Dilutive Funding - GuruFocus
REGENXBIO secures $150 million to extend cash runway - Investing.com Australia
RegenXBio Secures $250M Royalty Monetization Deal - TipRanks
REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million - Eagle-Tribune
Regenxbio Announces Strategic Royalty Monetization Agreement For Up To $250 Million - marketscreener.com
REGENXBIO's $250M Royalty Deal Extends Cash Runway to 2027, Funds Multiple Late-Stage Programs - Stock Titan
Regenxbio signals RGX-202 pivotal enrollment surpasses 50% as company initiates commercial manufacturing in Q3 2025 - MSN
REGENXBIO’s Earnings Call Highlights Strong Start to Fiscal Year - TipRanks
REGENXBIO’s BLA for MPS II Gene Therapy RGX-121 Accepted for Priority Review by the FDA - CGTLive®
REGENXBIO Inc. Just Missed EPS By 64%: Here's What Analysts Think Will Happen Next - simplywall.st
Regenxbio BLA for Hunter syndrome candidate accepted by FDA - MSN
(RGNX) Proactive Strategies - news.stocktradersdaily.com
Earnings Miss: REGENXBIO Inc. Missed EPS By 64% And Analysts Are Revising Their Forecasts - Yahoo Finance
REGENXBIO Inc. (NASDAQ:RGNX) Q1 2025 Earnings Call Transcript - Insider Monkey
FDA Grants Priority Review to REGENXBIO's (RGNX) Gene Therapy fo - GuruFocus
FDA Accepts Biologics License Application For Mucopolysaccharidosis II Treatment - marketscreener.com
FDA Grants Priority Review to REGENXBIO's (RGNX) Gene Therapy for MPS II | RGNX Stock News - GuruFocus
FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment - Eastern Progress
US FDA accepts Regenxbio’s application for MPS II gene therapy - World Pharmaceutical Frontiers
Earnings call transcript: Regenxbio Q1 2025 misses forecasts, stock rises By Investing.com - Investing.com Nigeria
Stifel maintains buy on Regenxbio, reiterates $40 target - Investing.com Australia
Regenxbio (RGNX) Gains FDA Priority Review for RGX-121 BLA | RGN - GuruFocus
Transcript : REGENXBIO Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 05 - marketscreener.com
Stifel maintains buy on Regenxbio, reiterates $40 target By Investing.com - Investing.com India
REGENXBIO (RGNX) Reports Decrease in Q1 Revenue, Focuses on Gene Therapy Progress | RGNX Stock News - GuruFocus
REGENXBIO Reports First Quarter 2025 Financial Results and Recen - GuruFocus
Regenxbio Says Potential Hunter Syndrome Treatment Granted FDA Priority Review - marketscreener.com
Regenxbio stock rises on FDA’s priority review for MPS II therapy - Investing.com Nigeria
Regenxbio stock rises on FDA’s priority review for MPS II therapy By Investing.com - Investing.com South Africa
Regenxbio Inc Stock (RGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Regenxbio Inc Stock (RGNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mills Kenneth T. | Director |
May 12 '25 |
Sale |
7.91 |
20,602 |
163,046 |
475,103 |
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):